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012.12.0Abstract Patients with ischemic LV dysfunction are at increasing risk of adverse cardiac events
including sudden cardiac death. Proper revascularization of viable ischemic myocardium (compared
to medical treatment alone) is associated with improvement of LV systolic function, less cardiac
morbidities & mortalities and better functional capacity and well-being. Many diagnostic tools
are used in clinical practice for assessment of myocardial viability. Dobutamine stress Echocardiog-
raphy (DSE) is the most widely used technique, while delayed enhancement cardiac magnetic res-
onance (DE-CMR) and Flourine-18-ﬂuorodeoxy-glucose positron emission tomography (18F-
FDG PET) are considered the standard of care for assessment of myocardial viability. Our case
report illustrates how FDG PET myocardial viability assessment can guide therapy and improve
outcomes in a difﬁcult clinical and angiographic situation.
ª 2013 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
The prevalence of left ventricular (LV) dysfunction and resul-
tant congestive heart failure (CHF) is rapidly growing. At least
two thirds of cases of LV dysfunction are the result of coro-
nary artery disease (CAD).1–3 Those patients are at high risk
of subsequent cardiac death, severe morbidities and recurrent
hospitalizations for CHF. Also, they frequently have severeSchool of Medicine, Cardiol-
il.com (M.A. Mandour Ali).
tian Society of Cardiology.
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01limitations in their lifestyle and well-being. Several clinical
studies have shown that myocardial dysfunction in patients
with CAD may be reversible.5 After an initial ischemic injury,
various processes can occur that lead to LV dysfunction
including LV remodeling, impairment of energetics, metabolic
derangements and myocyte dysfunction with or without cell
death via necrosis and/or apoptosis. Pathophysiologic abnor-
malities other than cell necrosis/apoptosis are, to an extent,
reversible ‘‘which signiﬁes myocardial viability’’. Proper revas-
cularization of viable ischemic myocardium (compared to
medical treatment alone) is associated with improvement of
LV systolic function, less cardiac morbidities and mortalities;
including sudden cardiac death; and better functional capacity
and well-being. Many diagnostic tools are used in clinical prac-
tice for assessment of myocardial viability. Dobutamine Stress
Echocardiography (DSE) is the most widely used technique,
while delayed enhancement cardiac magnetic resonanceg by Elsevier B.V. All rights reserved.
118 M.A. Mandour Ali et al.(DE-CMR) and Flourine-18-ﬂuorodeoxy-glucose positron
emission tomography (18F-FDG PET) are considered the stan-
dard of care for assessment of myocardial viability.
2. Case report
A 56 year old gentleman who was a highly active aviation engi-
neer presented to his cardiologist with a vague history of chest
discomfort and shortness of breath. He is known to be a mild
diabetic and smoker. His clinical evaluation was fairly within
normal apart from soft systolic murmur of mild mitral regur-
gitation. His resting ECG showed poor progression of R waves
in chest leads (capture 1-A) and his resting transthoracic echo-
cardiography (TTE) showed markedly dilated LV with poor
systolic function (EF%= 26%), regional wall motion abnor-
malities and mild–moderate mitral regurgitation.
He was referred to DSE for assessment of myocardial
viability. DSE was reported as negative for evidence ofCapture 1 (A) Resting 12 lead ECG showing poor progression of R
DSE showing resting, low dose, high dose and recovery frames report
Capture 2 Resting 99mTc SPECT study showing large area of resting
wall ‘‘Large-sized defect’’.myocardial viability (Capture 1B). DSE included both low
and high dose DSE protocols. The high clinical suspicion of
advanced CAD was considered when the patient was referred
to resting 99mTc SPECT/18F-FDG PET myocardial viability
study.
3. Procedure
Resting 99mTc SPECT imaging was done using a JETStream
Philips SPECT gamma camera 70 min after the injection of
20 mCi of 99mTc Sestamibi using the gated non-attenuation cor-
rection protocol. PET myocardial metabolic study was done
using a Philips PET/CT machine 70 min after the injection of
8.2 mCi of 18F-FDGusing the non-gated attenuation correction
protocol. Baseline blood glucose (BG) level was 155 mg/dL and
the patient was given 25 gm of I.V glucose. His 30 min BG level
was 213 mg/dL. One I.U of regular Insulin was given I.V. Serial
BG measurements at 15, 30 and 45 min were 175, 154 andwaves in chest leads and intra-ventricular conduction delay. (B)
ed as negative for evidence of myocardial viability.
hypoperfusion involving the apex, antroapical segment and inferior
Capture 3 Flow/Metabolism mismatch consistent with signiﬁcant myocardial viability at the apex, antroapical segment and inferior
wall.
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was injected rapidly IV. Imaging was done 70 min after 18F-
FDG injection. Both images were sent through the server to a
processing work station with a commercial Emory cardiac tool-
box (ECTB) software. ECTB accepts SPECT and PET to be
processed together as ﬂow and metabolic images.Capture 4 Flow/Metabolism mismatch consistent with signiﬁcant m
wall. Regional resting myocardial perfusion pattern points to the culp4. Resting 99mTc SPECT study
The study showed a large area of resting hypoperfusion at the
inferior wall, apex, antroapical and infroapical segments.
Semiquantitative analysis estimated the total defect size to be
21–23% ‘‘Large-size defect’’ (Capture 2). Functional analysisyocardial viability at the apex, antroapical segment and inferior
rit coronary lesion (which is the RCA in this case).
120 M.A. Mandour Ali et al.showed EF%= 24%, EDV= 227 ml and ESV = 173 ml and
severe hypokinesis of the apex, antroapical and infroapical
segments.
5. Semiquantitative viability assessment
Comparing resting myocardial ﬂow (by 99mTc SPECT) to
myocardial metabolic activity (by 18F-FDG PET) showed sig-
niﬁcant viability at the apex, antroapical segment and inferior
wall. (Flow/Metabolism Mismatch) Captures 3 and 4.
A recommendation for coronary angiography and total
revascularization was made. Coronary angiography showed
severe multivessel disease involving LAD, diagonals, LCX,
both OM branches and a totally occluded proximal RCA with
good collateral circulation. Poor surgical targets were a major
problem against total surgical revascularization. Based on the
Resting 99mTc SPECT study, RCA was the culprit vessel and
successful PCI of RCA was done with good angiographic re-
sults. (see Capture 5)
Clinical follow up of the patient after 6 months showed
marked improvement of symptoms, functional capacity, LVCapture 5 Coronary angiogram showing normal left main, diffusely
(diabetic) vessels with poor surgical targets. Successful PCI of the culdimensions and systolic function. TTE at 6 months follow up
showed mild hypokinesis of the apex and inferior wall,
EF%= 43% and smaller LV size.
Follow up resting 99mTc SPECT study showed a marked
improvement of resting myocardial blood ﬂow at the inferior
wall, apex and antroapical segment. As well, there is a marked
improvement of LV dimensions and systolic function (esti-
mated EF%= 40%). (Capture 6)6. Discussion
The term myocardial hibernation was introduced by Rahimto-
ola et al. to describe a condition of chronic sustained abnormal
contraction attributable to chronic hypoperfusion in patients
who have CAD and in whom revascularization leads to recov-
ery of LV systolic function.8 The pathophysiology underlying
this phenomenon is thought to be due to down-regulation of
function in the presence of reduced blood ﬂow and oxygen
supply. Accordingly, myocardial hibernation is considered a
state of ‘‘contraction-ﬂow match’’ which could be illustrated,diseased left system and proximal total occlusion of RCA. Small
prit vessel (RCA) was done with good angiographic results.
Capture 6 Resting gated 99mTc SPECT study at 6 months follow up showing marked improvement of resting myocardial perfusion at
the inferior wall, apex and antroapical segment as well as LV dimensions and systolic function.
Table 1 Different PET tracers11.
Mechanism Radionuclide Pharmaceutical Physical half- life Production
Perfusion Nitrogen-13 Ammonia 10 min Cyclotron
Rubidium-82 Rubidium 76 s Generator
Oxygen-15 Water 110 s Cyclotron
Glucose metabolism Fluorine-18 Fluorodeoxyglucose 110 min Cyclotron
Fatty acid metabolism Carbon-11 Acetate 20 min Cyclotron
Carbon-11 Palmitate 20 min Cyclotron
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maintain cell viability during low ﬂow state.8,9
LV EF% as well as the size and severity of myocardial
ischemia are the cardinal predictors of cardiac morbidity and
mortality among patients with CAD. In the CASS (Coronary
Artery Surgery Study) registry, for the cohort of patients trea-
ted with medical therapy, those with a LV EF%P 50% had a
10-year survival of approximately 90%, compared with a sur-
vival of 60% for those with an EF% between 35% and 49%.
Those with LV EF%< 35% had a 10 year survival of 30%
(p< 0.001).11 Patients with poor LV systolic function and
hibernating myocardium had the poorest prognosis if they
were not referred to proper revascularization procedure.12,13
Di Carli et al. reported that medically treated patients who
had PET evidence of myocardial viability had markedly lower
annual survival of 50%, compared with 92% for patients with-
out evidence of viability (p= 0.007). Patients with evidence of
myocardial viability who underwent proper revascularization
had a higher survival rate than those treated medically (88%
versus 50%, p= 0.03).5,6
Allman et al in ameta-analysis of 3088 patientswith depressed
LV systolic function, reported that the annual mortality rate for
patients with viabilitywhowere treatedmedicallywas 16%, com-
pared with 3.2% for patients who underwent revascularization
(p< 0.0001). Conversely, for patients without viable myocar-
dium, there was a trend toward increased mortality in patients
whounderwent revascularization, 7.7%versus 6.2% (p= 0.23).1Many imaging modalities are now available for the
assessment of myocardial viability; rest-delayed and reinjec-
tion thallium imaging; 99mTc Sestamibi imaging; metabolic
imaging with PET; DSE and DE-CMR, are all helpful in
making clinical decision and guiding therapy. Generally,
DSE is the most widely available tool. It has a slightly lower
sensitivity but an excellent speciﬁcity (good positive test).
Currently, FDG PET and DE-CMR techniques are consid-
ered the standard of care in assessment of myocardial
viability.
18F-FDG is an analog of glucose, which is transported into
cells via a speciﬁc glucose membrane transporter and is phos-
phorylated by hexokinase. Unlike glucose, FDG is trapped
and is not metabolized further. Its accumulation is an index
of glucose uptake.6 Assessment of viability by the PET tech-
nique uses regional metabolic activity, regional myocardial
blood ﬂow and regional myocardial function to classify viabil-
ity patterns into:
 Normal tissue showing normal function, perfusion and
metabolism.
 Stunned myocardium showing poor function, preserved
ﬂow, and almost normal FDG uptake.
 Hibernating myocardium showing poor perfusion and func-
tion, and almost normal FDG uptake. (Mismatched defect)
 Infarcted myocardium shows a matched decrease in perfu-
sion, function and metabolism. (Matched defect).
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The following table shows different PET tracers used in clinical
practice either as ﬂow or metabolic tracers: (see Table 1).
In clinical practice, 99mTc sestamibi SPECT study is com-
monly used to assess the resting myocardial blood ﬂow instead
of PET ﬂow tracers due to their limited availability.
Observational studies have suggested that 18F-FDG PET
can help identify patients at high risk for cardiac events.4–13
The randomized controlled PET and Recovery Following
Revascularization (PARR2) trial demonstrated a trend toward
reduction of cardiac events with FDG-assisted decision mak-
ing14–16.
References
1. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial
viability testing and impact of revascularization on prognosis in
patients with coronary artery disease and left ventricular dysfunc-
tion: a meta-analysis. J Am Coll Cardiol 2002;39:1151–8.
2. Deedwania PC. The key to unraveling the mystery of mortality in
heart failure. An integrated approach. Circulation 2003;107:
1719–21.
3. Demirkol MO. Myocardial viability by SPECT and PET in LV
dysfunction. Anadolu Kardiyol Derg 2008;8(2):60–70.
4. Desideri A, Cortigiani L, Christen A, et al. The extent of
perfusion-F18-ﬂuorodeoxyglucose positron emission tomography
mismatch determines mortality in medically treated patients with
chronic ischemic left ventricular dysfunction. J Am Coll Cardiol
2005;46:1264–9.
5. DiCarli MF, Davidson M, Little R, et al. Value of metabolic
imaging with positron emission tomography for evaluating prog-
nosis in patients with coronary artery disease and left ventricular
dysfunction. Am J Cardiol 1994;73:527–33.
6. DiCarli MF, Maddahi J, Rokhsar S, et al. Long term survival of
patients with coronary artery disease and left ventricular dysfunc-tion: implications for the role of myocardial viability assessment in
management decisions. J Thorac Cardiovasc Surg 1998;116:
997–1004.
7. Haas F, Haehnel CJ, Picker W, et al. Preoperative positron
emission tomographic viability assessment and perioperative and
postoperative risk in patients with advanced ischemic heart
disease. J Am Coll Cardiol 1997;30:1693–700.
8. Heusch G, Schulz R, Rahimtoola SH. Myocardial hibernation: a
delicate balance. Am J Physiol Heart Cir Physiol 2005;288:
H984–99.
9. Lee KS, Marwick TH, Cook SA, et al. Prognosis of patients with
left ventricular dysfunction, with and without viable myocardium
after myocardial infarction: relative efﬁcacy of medical therapy
and revascularization. Circulation 1994;90:2687–94.
10. Machac J, Bacharach SL, Bateman TM, et al. Positron emission
tomography myocardial perfusion and glucose metabolism imag-
ing. J Nucl Cardiol 2006;13:e121–51.
11. Schinkel AF, Poldermans D, Elhendy A, Bax JJ. Assessment of
myocardial viability in patients with heart failure. J Nucl Med
2007;48:1135–46.
12. Schinkel AF, Bax JJ, Poldermans D, et al. Hibernating myocar-
dium: diagnosis and patient outcomes. Curr Probl Cardiol 2007;32:
375–410.
13. Schwaiger M, Nekolla SG. Coronary artery disease: tissue
viability and perfusion. In: Von Schulthess GK, editor. Molecular
Anatomic Imaging. PET-CT and SPECT-CT Integrated Modality
Imaging. Philadelphia, PA: Lippincott; 2007. p. 227–43.
14. Tarakji KG, Brunken R, McCarthy PM, et al. Myocardial
viability testing and the effect of early intervention in patients
with advanced left ventricular systolic dysfunction. Circulation
2006;113:230–7.
15. Travin MI, Bergmann SR. Assessment of myocardial viability.
Semin Nucl Med 2005;2:2–19.
16. Yoshida K, Gould KL. Quantitative relation of myocardial infarct
size and myocardial viability by positron emission tomography to
left ventricular ejection fraction and 3-year mortality with and
without revascularization. J Am Coll Cardiol 1993;22:984–97.
